Pregnancy and epilepsy: scientists track how a key drug moves through the body

NCT ID NCT04117425

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study looks at how the epilepsy drug levetiracetam is processed in pregnant women and how much reaches the baby. Researchers will collect blood and saliva samples throughout pregnancy and at delivery, plus cord blood and amniotic fluid. The goal is to create a model that could one day help doctors personalize doses to keep both mother and baby safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

levetiracetam

What this could lead to

If successful, this could help doctors adjust levetiracetam doses during pregnancy to keep seizure control stable while minimizing risks.

What could go wrong

This is a small observational study (14 participants) focused on measuring drug levels, not testing a new treatment. Results may not apply to all pregnant women with epilepsy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY IN PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • hospital Cochin

    Paris, 75014, France